RESPONSE OF RETINAL SENSITIVITY TO RANIBIZUMAB TREATMENT OF MACULAR EDEMA AFTER ACUTE BRANCH RETINAL VEIN OCCLUSION
RESPONSE OF RETINAL SENSITIVITY TO RANIBIZUMAB TREATMENT OF MACULAR EDEMA AFTER ACUTE BRANCH RETINAL VEIN OCCLUSION
复制标题
DOI：
10.1097/iae.0b013e3182794b06
复制
发表时间：
2013-06-01
影响因子：
3.3
通讯作者：
Schmidt-Erfurth, Ursula
中科院分区：
文献类型：
--
作者：
Mylonas, Georgios;Sacu, Stefan;Schmidt-Erfurth, Ursula
目的：评估视网膜分支静脉阻塞继发的急性黄斑水肿患者接受玻璃体内雷珠单抗治疗（Lucentis；Novartis）12个月随访期间微视野检查的变化。方法：视网膜分支静脉阻塞继发黄斑水肿的患者接受玻璃体内注射0.5 mg雷珠单抗（0.05 mL）。在一年的随访期内，每月进行最佳矫正视力、Spectralis OCT（海德堡工程）和彩色眼底照相检查。在基线、3 个月和 12 个月时通过微视野检查（Nidek，MP-1）记录黄斑功能。结果：统计分析中纳入了 20 名不缺乏微视野检查结果的患者的数据。绝对暗点面积从基线时的 16% 减少至第 3 个月时的 11.7%，并在整个研究期间保持稳定 (P > 0.05)。治疗后平均差别光阈值显着改善，从基线时的 9.47 dB 提高到 12 个月时的 12.53 dB (P < 0.001)。基线和 12 个月随访时，最佳矫正视力与中央毫米厚度和平均视网膜敏感度显着相关。结论：除了解剖恢复和视力提高之外，玻璃体内注射雷珠单抗还可以改善视网膜分支静脉阻塞后急性黄斑水肿患者的中央黄斑功能。
Purpose: To evaluate microperimetry changes in patients with acute macular edema secondary to branch retinal vein occlusion during a follow-up period of 12 months with intravitreal ranibizumab treatment (Lucentis; Novartis).Methods: Patients with macular edema secondary to branch retinal vein occlusion received an intravitreous injection of 0.5 mg of ranibizumab (0.05 mL). Best-corrected visual acuity, Spectralis OCT (Heidelberg Engineering), and color fundus photography were performed at monthly intervals over a follow-up period of 1 year. Macular function was documented by microperimetry (Nidek, MP-1) at baseline, 3, and 12 months.Results: Data of 20 patients without lack of microperimetry results were included to the statistical analyses. The size of the area of absolute scotoma was reduced from 16% at baseline to 11.7% at Month 3 and remained stable in the entire study duration (P > 0.05). Mean differential light threshold improved significantly under therapy from 9.47 dB at baseline to 12.53 dB at 12 months (P < 0.001). Best-corrected visual acuity correlated significantly with central millimeter thickness and mean retinal sensitivity at baseline and at 12-month follow-up visits.Conclusion: In addition to anatomical restoration and increased visual acuity, intravitreal ranibizumab also improved the central macular function in patients with acute macular edema after branch retinal vein occlusion.